top of page

Data suggest gene, cell therapy trial initiations in Europe lag behind America — here's why

Updated: Nov 20, 2020

4BIO's Dmitry Kuzmin and Owen Smith enjoyed speaking to Natalie Grover at Endpoints on the state of cell & gene therapy trials in Europe and the US following yesterday’s report from the Alliance for Regenerative Medicine. We also discussed the trends 4BIO expects to see as more treatments are developed.

Comments


ARCHIVE
SEARCH BY TAGS
FOLLOW US
Invest_europe.png
4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342
© 2015-2025 by 4BIO Partners LLP
bottom of page